A carregar...
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the prese...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Portland Press Ltd.
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3507260/ https://ncbi.nlm.nih.gov/pubmed/23101586 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20121513 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|